Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Panlabs Biologics Inc. is a professional biotech company originating from Taiwan, China. Its predecessor was Panlabs Taiwan, founded in 1971, with more than 50 years of experience in industrial microbial strain improvement and fermentation technology R&D. It currently focuses on CRO/CDMO services in the microbiology field, while independently developing high-value bioactive raw materials. Its clients cover multiple industries globally including pharmaceuticals, agriculture, environmental protection, and new materials, and it has provided services for well-known international pharmaceutical companies such as Eli Lilly, Merck, Pfizer, and GSK.
The company's core services cover the entire process from strain screening and improvement, fermentation process optimization, downstream purification, semi-synthesis, to pilot scale-up production. It has a strain resource bank of more than 20,000 actinomycetes and fungal strains, and none of these strains are restricted by the Nagoya Protocol, making international collaboration very convenient. In addition to custom R&D services, Panlabs also specializes in the supply of cytotoxic payload raw materials for ADC drugs. It has already achieved kilogram-scale production of multiple key ADC intermediates including ansamitocin P-3 and calicheamicin, and also provides functional biological raw materials such as recombinant proteins, enzyme preparations, and probiotic extracellular vesicles, as well as functional pet food.
Strengths: Panlabs has profound technical accumulation and rich project experience. Its integrated service model helps customers quickly complete the transition from R&D to pilot production, it has a clear advantage in strain resources, and its customized services are very flexible.
Weaknesses: No pricing information is publicly available on the official website, requiring one-on-one communication which results in low communication efficiency; the official website only supports English, which is not user-friendly for domestic users in China; the company itself only has 50-500L pilot production capacity, so large-scale mass production relies on partner factories.
This website is currently directly accessible in China, and is well suited for the microbiology-related R&D projects and custom development needs of innovative drug intermediates from small and medium-sized biopharmaceutical enterprises and startups around the world.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on panlabsbiologics.com official site.
panlabsbiologics.com is an Unknown Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach panlabsbiologics.com directly.